Ustekinumab versus adalimumab for induction and maintenance therapy in moderate-to-severe Crohn’s disease: the SEAVUE study. - Sands, B E; Irving, P M; Hoops, T
Abstract presented at: Digestive Disease Week; May 21-23, 2021; Virtual Meeting